Beck, T M <br/><br/>
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.  [electronic resource] 

 -  Cancer investigation  1997 
 - 297-303 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0735-7907 
<br/><br/><label>Standard No.: </label>10.3109/07357909709039729  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antiemetics--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Appetite--drug effects<br/>Cyclophosphamide--administration & dosage<br/>Double-Blind Method<br/>Doxorubicin--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Male<br/>Methotrexate--administration & dosage<br/>Middle Aged<br/>Nausea--chemically induced<br/>Neoplasms--drug therapy<br/>Ondansetron--adverse effects<br/>Time Factors<br/>Vomiting--chemically induced